FDA acceptance of VCTE as trial endpoint can accelerate MASH drug development: GlobalData EP News Bureau Sep 1, 2025 GlobalData notes FDA’s acceptance of VCTE as a surrogate endpoint may reduce reliance on biopsies, ease patient enrolment, and…
